炎症性肠病合并非酒精性脂肪性肝病的研究进展
Research Progress on Inflammatory Bowel Disease Complicated with Non-Alcoholic Fatty Liver Disease
DOI: 10.12677/ACM.2023.1361327, PDF,   
作者: 马有泉：青海大学研究生院，青海 西宁 ；荣光宏*：广东医科大学附属东莞第一医院消化内科，广东 东莞
关键词: 炎症性肠病；非酒精性脂肪性肝病；溃疡性结肠炎；克罗恩病；Inflammatory Bowel Disease； Nonalcoholic Fatty Liver Disease； Ulcerative Colitis； Crohn’s Disease
摘要: 炎症性肠病(IBD)是一种慢性、复发性肠道疾病，包括克罗恩病(CD)和溃疡性结肠炎(UC)两种亚型。尽管IBD以前被认为是一种西方疾病，但近些年在亚洲等发展中地区IBD的发病率和患病率呈上升趋势。在IBD患者中经常观察到肝脏和胆道疾病，由于炎症过程或与其基础疾病相关的生态失调，患有这些慢性、免疫介导的肠道炎症的患者可能会增加患非酒精性脂肪性肝病(NAFLD)的风险。此文就IBD与NAFLD的最新研究进展进行探讨作一综述，旨在为临床治疗提供参考，更加科学地管理IBD患者。
Abstract: Inflammatory bowel disease (IBD) is a chronic, relapsing intestinal disorder that includes two sub-types of Crohn’s disease (CD) and ulcerative colitis (UC). Although previously considered a Western disease, the incidence and prevalence of IBD has been on the rise in recent years in developing re-gions such as Asia. Liver and biliary diseases are often observed in patients with IBD, and patients with the chronic, immune-mediated intestinal inflammation may be at increased risk of developing non-alcoholic fatty liver disease (NAFLD) due to inflammatory processes or ecological dissonance associated with their underlying disease. This article reviews the latest research progress of IBD and NAFLD, aiming to provide reference for clinical treatment and more scientific management of patients with IBD.
文章引用：马有泉, 荣光宏. 炎症性肠病合并非酒精性脂肪性肝病的研究进展[J]. 临床医学进展, 2023, 13(6): 9482-9488. https://doi.org/10.12677/ACM.2023.1361327

参考文献

[1] Ng, S.C., Shi, H.Y., Hamidi, N., Underwood, F.E., Tang, W., Benchimol, E.I., Panaccione, R., Ghosh, S., Wu, J.C.Y., Chan, F.K.L., Sung, J.J.Y. and Kaplan, G.G. (2017) Worldwide Incidence and Prevalence of Inflammatory Bowel Dis-ease in the 21st Century: A Systematic Review of Population-Based Studies. Lancet, 390, 2769-2778. [Google Scholar] [CrossRef] 
[2] Pasquali, S. and Gronchi, A. (2017) Neoadjuvant Chemo-therapy in Soft Tissue Sarcomas: Latest Evidence and Clinical Implications. Therapeutic Advances in Medical Oncology, 9, 415-429. [Google Scholar] [CrossRef] [PubMed]
[3] Ye, Q., Zou, B., Yeo, Y.H., Li, J., Huang, D.Q., Wu, Y., Yang, H., Liu, C., Kam, L.Y., Tan, X.X.E., Chien, N., Trinh, S., Henry, L., Stave, C.D., Hosaka, T., Cheung, R.C. and Nguyen, M.H. (2020) Global Prevalence, Incidence, and Outcomes of Non-Obese or Lean Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. The Lancet Gastroenterology and Hepatology, 5, 739-752. [Google Scholar] [CrossRef] 
[4] Schwabe, R.F., Tabas, I. and Pajvani, U.B. (2020) Mecha-nisms of Fibrosis Development in Nonalcoholic Steatohepatitis. Gastroenterology, 158, 1913-1928. [Google Scholar] [CrossRef] [PubMed]
[5] Hardy, T., Oakley, F., Anstee, Q.M. and Day, C.P. (2016) Non-alcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum. Annual Review of Pathology: Mechanisms of Disease, 11, 451-496. [Google Scholar] [CrossRef] [PubMed]
[6] Zamani, M., Alizadeh-Tabari, S., Singh, S. and Loomba, R. (2022) Meta-Analysis: Prevalence Of, and Risk Factors For, Non-Alcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Disease. Alimentary Pharmacology & Therapeutics, 55, 894-907. [Google Scholar] [CrossRef] [PubMed]
[7] Perdomo, C.M., Frühbeck, G. and Escalada, J. (2019) Impact of Nutritional Changes on Nonalcoholic Fatty Liver Disease. Nutrients, 11, Article No. 677. [Google Scholar] [CrossRef] [PubMed]
[8] Zhao, H., Yang, A., Mao, L., Quan, Y., Cui, J. and Sun, Y. (2020) As-sociation between Dietary Fiber Intake and Non-Alcoholic Fatty Liver Disease in Adults. Frontiers in Nutrition, 7, Arti-cle 593735. [Google Scholar] [CrossRef] [PubMed]
[9] Suk, K.T. and Kim, D.J. (2019) Gut Microbiota: Novel Therapeutic Target for Nonalcoholic Fatty Liver Disease. Expert Review of Gastroenterology & Hepatology, 13, 193-204. [Google Scholar] [CrossRef] [PubMed]
[10] Zhang, Z., Thorne, J.L. and Moore, J.B. (2019) Vitamin D and Nonalcoholic Fatty Liver Disease. Current Opinion in Clinical Nutrition and Metabolic Care, 22, 449-458. [Google Scholar] [CrossRef] 
[11] Reilly, N.R., Lebwohl, B., Hultcrantz, R., Green, P.H. and Ludvigsson, J.F. (2015) Increased Risk of Non-Alcoholic Fatty Liver Disease after Diagnosis of Celiac Disease. Journal of Hepatology, 62, 1405-1411. [Google Scholar] [CrossRef] [PubMed]
[12] Kang, M.K., Kim, K.O., Kim, M.C., Park, J.G. and Jang, B.I. (2020) Sarcopenia Is a New Risk Factor of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Dis-ease. Digestive Diseases, 38, 507-514. [Google Scholar] [CrossRef] [PubMed]
[13] Ampong, I., Watkins, A., Gutierrez-Merino, J., Ikwuobe, J. and Griffiths, H.R. (2020) Dietary Protein Insufficiency: An Important Consideration in Fatty Liver Disease? The British Journal of Nutrition, 123, 601-609. [Google Scholar] [CrossRef] 
[14] Pälve, K.S., Pahkala, K., Suomela, E., Aatola, H., Hulkkonen, J., Juonala, M., Lehtimäki, T., Rönnemaa, T., Viikari, J.S.A., Kähönen, M., Hutri-Kähönen, N., Telama, R., Tammelin, T. and Raitakari, O.T. (2017) Cardiorespiratory Fitness and Risk of Fatty Liver: The Young Finns Study. Medicine & Sci-ence in Sports & Exercise, 49, 1834-1841. [Google Scholar] [CrossRef] 
[15] Partridge, D., Lloyd, K.A., Rhodes, J.M., Walker, A.W., Johnstone, A.M. and Campbell, B.J. (2019) Food Additives: Assessing the Impact of Exposure to Permitted Emulsifiers on Bowel and Metabolic Health—Introducing the FADiets Study. Nutrition Bulletin, 44, 329-349. [Google Scholar] [CrossRef] [PubMed]
[16] Aron-Wisnewsky, J., Warmbrunn, M.V., Nieuwdorp, M. and Clément, K. (2020) Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity? Gastroenterology, 158, 1881-1898. [Google Scholar] [CrossRef] [PubMed]
[17] Likhitsup, A., Dundulis, J., Ansari, S., El-Halawany, H., Mi-chelson, R., Hutton, C., Kennedy, K., Helzberg, J.H. and Chhabra, R. (2019) Prevalence of Non-Alcoholic Fatty Liver Disease on Computed Tomography in Patients with Inflammatory Bowel Disease Visiting an Emergency Department. Annals of Gastroenterology, 32, 283-286. [Google Scholar] [CrossRef] [PubMed]
[18] McCracken, E., Monaghan, M. and Sreenivasan, S. (2018) Patho-physiology of the Metabolic Syndrome. Clinics in Dermatology, 36, 14-20. [Google Scholar] [CrossRef] [PubMed]
[19] Yorulmaz, E., Adali, G., Yorulmaz, H., Ulasoglu, C., Ta-san, G. and Tuncer, I. (2011) Metabolic Syndrome Frequency in Inflammatory Bowel Diseases. Saudi Journal of Gas-troenterology, 17, 376-382. [Google Scholar] [CrossRef] [PubMed]
[20] Fröhlich, M., Imhof, A., Berg, G., Hutchinson, W.L., Pepys, M.B., Boeing, H., Muche, R., Brenner, H. and Koenig, W. (2000) Association between C-Reactive Protein and Features of the Metabolic Syndrome: A Population-Based Study. Diabetes Care, 23, 1835-1839. [Google Scholar] [CrossRef] [PubMed]
[21] Barron, L., Courtney, C., Bao, J., Onufer, E., Panni, R.Z., Aladeg-bami, B. and Warner, B.W. (2018) Intestinal Resection-Associated Metabolic Syndrome. Journal of Pediatric Surgery, 53, 1142-1147. [Google Scholar] [CrossRef] [PubMed]
[22] Allard, J., Le Guillou, D., Begriche, K. and Fromenty, B. (2019) Drug-Induced Liver Injury in Obesity and Nonalcoholic Fatty Liver Disease. Advances in Pharmacology, 85, 75-107. [Google Scholar] [CrossRef] [PubMed]
[23] Nielsen, O.H. and Ainsworth, M.A. (2013) Tumor Ne-crosis Factor Inhibitors for Inflammatory Bowel Disease. The New England Journal of Medicine, 369, 754-762. [Google Scholar] [CrossRef] 
[24] Ben-Horin, S., Kopylov, U. and Chowers, Y. (2014) Optimizing Anti-TNF Treatments in Inflammatory Bowel Disease. Autoimmunity Reviews, 13, 24-30. [Google Scholar] [CrossRef] [PubMed]
[25] Nakase, H., Hirano, T., Wagatsuma, K., Ichimiya, T., Yamakawa, T., Yokoyama, Y., Hayashi, Y., Hirayama, D., Kazama, T., Yoshii, S. and Yamano, H.-O. (2021) Artificial Intelli-gence-Assisted Endoscopy Changes the Definition of Mucosal Healing in Ulcerative Colitis. Digestive Endoscopy, 33, 903-911. [Google Scholar] [CrossRef] [PubMed]
[26] Neurath, M.F. (2014) New Targets for Mucosal Healing and Therapy in Inflammatory Bowel Diseases. Mucosal Immunology, 7, 6-19. [Google Scholar] [CrossRef] [PubMed]
[27] Okamoto, R. and Watanabe, M. (2016) Investigating Cell Therapy for In-flammatory Bowel Disease. Expert Opinion on Biological Therapy, 16, 1015-1023. [Google Scholar] [CrossRef] [PubMed]
[28] van der Windt, D.J., Sud, V., Zhang, H., Tsung, A. and Huang, H. (2018) The Effects of Physical Exercise on Fatty Liver Disease. Gene Expression, 18, 89-101.
[29] Ji, H.-F., Sun, Y. and Shen, L. (2014) Effect of Vitamin E Supplementation on Aminotransferase Levels in Patients with NAFLD, NASH, and CHC: Results from a Meta-Analysis. Nutrition, 30, 986-991. [Google Scholar] [CrossRef] [PubMed]

为你推荐